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Conclusion: Treatment intensification in NSCLC via targeted 
dose escalation with modern delivery techniques offers the 
potential for a significant increase in tumour control 
probability without a clinically significant increase in 
predicted OAR toxicity. 
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Purpose or Objective: We investigated the associations 
between acute and late genitourinary (grade ≥ 2) toxicity and 
clinical and dosimetric parameters in three-dimensional 
conformal radiotherapy for localized prostate cancer in order 
to carry out a dose-volume response evaluation. A dose-
volume parameters analysis of the bladder of patients 
subjected to prostate cancer radiotherapy was reported. 
 
Material and Methods: We considered 86 patients 
consecutively treated with high dose conformal image guided 
radiation therapy for localized prostate cancer. For the 
purpose of our analysis, we defined two bladder volumes: 
“whole bladder”, i.e. the bladder in its entirely as a solid 
organ, and “inferior bladder”, corresponding to the only 
distal part of the bladder. We carried out an univariate 
analysis between acute and late genitourinary toxicity and 
clinical parameters (age, “whole bladder” and “inferior 
bladder” volumes, smoking status, pre-radiotherapy urinary 
symptoms, hormonal therapy). We used the point biserial 
correlation coefficient to correlate dose-volume parameters 
(Vx) and genitourinary (grade ≥ 2) toxicity. Finally, a fitting 
of the normal tissue complication probability (NTCP) cut-off 
volume model with toxicity data was performed. 
 
Results: Mean follow-up was 51.9 months (range: 41.9–75.4 
months). In 60 patients we observed an acute genitourinary 
toxicity (grade ≥2), while a late genitourinary toxicity (grade 
≥2) was recorded in 6 patients. At univariate analysis, we 
found a correlation between acute genitourinary toxicity and 
smoking status (P < 0.001). Statistically significant 
associations (P < 0.05) between late genitourinary toxicity 
and Vx dose levels were calculated from 77 Gy and 77.5 Gy, 
for the “whole bladder” and the “inferior bladder”, 
respectively. For acute toxicity, we found a statistically 
significant correlation with the dose of 80 Gy (P < 0.05), for 
both “whole bladder” and “inferior bladder”. From the NTCP 
cut-off volume model we detected a bladder volume of 6 cc 
as the cut-off volume corresponding to a late genitourinary 
toxicity of 50% at doses ≥77 Gy. 
 
Conclusion: Genitourinary toxicity seems to be correlated 
with bladder maximal doses, quantified as hotspots. 
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Purpose or Objective: Cancer stem cells (CSCs) and hypoxia 
are known contributors of tumour resistance in radiotherapy. 
These parameters influence the radiotherapy schedule for 
optimal tumour control. Since hypofractionation is becoming 
increasingly popular among solid tumours, our aim is to 
evaluate the efficacy of hypo- versus hyperfractionated 
radiotherapy (RT) on hypoxic head and neck cancer (HNC). 
 
Material and Methods: An in silico HNC was developed 
starting from a CSC. To grow a tumour with biologically valid 
parameters, the CSC generates all heterogeneous lineages of 
a tumour, with a probability of CSC symmetrical division 
1.9%, mean cell cycle time 33h and volume doubling time 52 
days. Pre-treatment CSC percentage is 5.9%. Four different 
fractionation schedules have been simulated as shown in 
Table 1. Hypoxic tumours with partial oxygen tension values 
ranging from 3 to 9 mmHg have been treated and tumour 
control assessed.  
 
Table 1. Dose fractionation schedules simulated in current 
study 
 
 
 
Results: Treatment resistance is determined by the interplay 
between CSCs and hypoxia. While the modelled conventional 
and hypofractionated RT schedules are biologically 
equivalent, hypofractionation is more efficient on CSC kill 
than conventional treatment. However, for moderately 
hypoxic tumours (6 mmHg partial oxygen tension) (see figure 
1) only hyperfractionated RT offers full control on CSC 
population within the clinically required treatment time. This 
observation might be explained by the advantage of two 
fractions a day through (i) overcoming tumour repopulation 
between consecutive doses, (ii) redistribution of surviving 
cells along the cycle; (iii) better reoxygenation. For each 
decrease in mmHg the number of fractions needed for 
tumour control increases exponentially. This behaviour is also 
influenced by the percentage of CSC, which changes during 
radiotherapy. Thus a tumour with a mean oxygen tension 
below 6 mmHg and a pre-treatment CSC population of 5.9% 
needs a greater than 84Gy dose (overall dose given via 
hyperfractionated RT) or the addition of adjuvant therapies 
in order to be eradicated. 
Figure 1. Radiotherapy schedules for hypoxic HNC with 6 
mmHg mean partial oxygen tension. 
 
 
 
Conclusion: Hypoxic HNC are better controlled by 
hyperfractionated than by hypofractionated RT. However, 
oxic and mildly hypoxic tumours could benefit from 
hypofractionation, which reduces overall treatment time and 
normal tissue effects. The interplay between CSCs and 
hypoxia dictates the RT treatment strategy for optimal 
tumour control. 
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